Raid Aljumaily to Antibodies, Monoclonal
This is a "connection" page, showing publications Raid Aljumaily has written about Antibodies, Monoclonal.
Connection Strength
0.443
-
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest New Drugs. 2019 06; 37(3):461-472.
Score: 0.137
-
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018 01; 19(1):51-64.
Score: 0.130
-
Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res. 2013 Apr 15; 73(8):2457-2467.
Score: 0.093
-
Optimal management of bone metastases in prostate cancer. Curr Oncol Rep. 2011 Jun; 13(3):222-30.
Score: 0.083